Company Restructuring - Sarepta Therapeutics 宣布重大重组计划 [1] Stock Market Impact - Sarepta Therapeutics 股票在盘后交易中飙升近 40% [1]

NEW YORK, July 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE: https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=156859&from=4 CLASS PERIOD: June 22, 2023 to ...

Core Insights - Sarepta Therapeutics announced a significant restructuring plan, including laying off 500 employees, which is nearly 40% of its workforce, and halting several gene therapy programs, leading to an expected annual cost savings of over $400 million by 2026 [2][3]. Financial Performance - The company's stock rose 33% in after-hours trading following the announcement, indicating investor relief at management's swift actions to address the financial situation [2][3]. - Sarepta's shares have decreased by 88% over the past year, and the restructuring is expected to improve its cash burn rate and address a concerning debt-to-equity ratio of 63% [3]. Strategic Focus - The restructuring aims to transition Sarepta from a high-spending, pipeline-heavy biotech to a streamlined organization focused on its Duchenne muscular dystrophy franchise [4]. - The company is increasing its reliance on Elevidys, which accounted for 43% of total revenues, raising potential risks if safety issues arise [4]. Valuation and Market Potential - Sarepta is currently trading at approximately 1x its trailing revenues, significantly undervalued compared to its three-year average price-to-sales ratio of 9x [5]. - Analysts have set an average price target of $48, indicating nearly 2x upside potential from the current price of $25, contingent on the success of cost-cutting measures [5]. Investment Risks - Sarepta is characterized as a high-risk biotech investment with extreme volatility, having experienced dramatic price fluctuations from $172 to recent lows around $18 [6]. - Historical performance shows underperformance compared to the S&P 500 during market declines, with significant drops during the 2022 Inflation Shock, 2020 COVID-19 Pandemic, and 2008 Global Financial Crisis [6].

Core Insights - Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has experienced significant volatility in recent years, which is common in the biotechnology sector due to the nature of drug development and approval processes [1]. Company Overview - The company is involved in the biotechnology industry, which is characterized by high levels of risk and potential reward, particularly for investors focused on long-term growth and short-term trading opportunities [1]. Investment Perspective - Investors in Sarepta Therapeutics may adopt various strategies, including Dividend Growth Investing (DGI), Dividend Reinvestment Plans (DRIP), and Growth at a Reasonable Price (GARP) for long-term investments, while also engaging in short-term trading for immediate gains [1].

Group 1 - Sarepta Therapeutics experienced a significant stock increase of over 35%, with a peak close to 60%, following the announcement of a workforce reduction of more than one-third and the continuation of its gene therapy for a fatal muscle disease under a warning for potential liver failure risks [1][2] - The company plans to implement a strategic restructuring and cost-saving measures, which include laying off 500 employees and pausing several drugs in its research pipeline, expected to save approximately $400 million annually [1] - The layoffs are intended to help maintain access to a $600 million revolving credit facility and generate cash flow to assist in repaying convertible bonds due in 2027 [1] Group 2 - In response to FDA requirements, Sarepta agreed to add a black box warning regarding liver failure risks to the label of its gene therapy Elevidys, which is the most severe safety warning for drugs [2] - Company executives indicated that the warning label appears to have addressed FDA concerns about using the therapy in ambulatory patients, while discussions continue regarding a new immunosuppressive regimen for non-ambulatory patients [2] - The CEO stated that Elevidys will remain on the market, and an analyst noted that the black box warning has avoided the worst-case scenario of the therapy being withdrawn [2]

Core Viewpoint - Class actions have been initiated for investors of Hims & Hers Health, Inc. and Sarepta Therapeutics, Inc. due to alleged misleading statements and undisclosed risks related to their business operations and products [1][4]. Hims & Hers Health, Inc. (NYSE: HIMS) - The class period for Hims & Hers is from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion of illegitimate versions of Wegovy, risking patient safety and jeopardizing its collaboration with Novo Nordisk [2][3]. - Defendants are accused of making materially misleading statements regarding the safety and availability of Wegovy for Hims subscribers, which lacked a reasonable basis [2][3]. Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - The class period for Sarepta is from June 22, 2023, to June 24, 2025, also with a lead plaintiff deadline of August 25, 2025 [4]. - Sarepta is alleged to have misled investors about the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [4]. - Significant safety risks associated with ELEVIDYS were not disclosed, leading to adverse events that prompted the company to halt clinical trials and attract regulatory scrutiny [4][5]. - Following reports of patient deaths related to ELEVIDYS, Sarepta's stock experienced significant declines, including a drop of $27.81 per share (27.44%) on March 18, 2025, and a further decline of $15.24 per share (42.12%) on June 15, 2025 [5][6].

Exhibit 99.1 Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label CAMBRIDGE, Mass., July 16, 2025 (BUSINESS WIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan designed to prioritize high-value, high impact programs, meet its 2027 financial obligations, and support its long-term financial v ...

Sarepta is cutting more than one-third of its workforce and will add a black box warning label to its gene therapy for a fatal muscle disorder after two patient deaths raised doubts about the future of the company https://t.co/FHYwnWd7ml ...

Core Viewpoint - A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and efficacy of its gene therapy treatment, ELEVIDYS, during the class period from June 22, 2023, to June 24, 2025 [1][2]. Allegations Against Defendants - The complaint claims that Sarepta made false or misleading statements and failed to disclose significant safety risks associated with ELEVIDYS [2]. - It is alleged that the trial protocols for ELEVIDYS did not adequately detect severe side effects, leading to potential regulatory scrutiny and halting of recruitment and dosing in trials [2]. - The severity of adverse events from ELEVIDYS treatment is said to have materially misled investors regarding the therapy's approval prospects [2]. Lead Plaintiff Process - Investors in Sarepta have until August 25, 2025, to seek appointment as a lead plaintiff, representing the class in the litigation [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest and who are representative of the class [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=156709&from=3 CLASS PERIOD: June 22, 2 ...